Atopic Dermatitis Market Summary
- Atopic Dermatitis Market Size in 7MM was around ~USD 17 billion in 2023, which is expected to increase by 2034 during the study period (2020–2034) in the 7MM.
- The leading Atopic Dermatitis Companies such as Atopic Dermatitis Market includes Sanofi, Regeneron Pharmaceuticals, Pfizer, Japan Tobacco and Torii Pharmaceutical, Eli Lilly and Company, AbbVie, LEO Pharma, Incyte Corporation, Arena Pharmaceuticals, Oneness Biotech, Galderma, DS Biopharma, Janssen, Kymab, Arcutis Biotherapeutics, Qurient, Cara Therapeutics, Vanda Pharmaceuticals, and others.
Atopic Dermatitis Market and Epidemiology Analysis
- Atopic Dermatitis, often referred to as eczema, is a chronic (long-lasting) disease that causes inflammation, redness, and irritation of the skin. It is a common condition that usually begins in childhood; however, anyone can get the disease at any age.
- ~40% of the Atopic Dermatitis Prevalent Population is ≤ 18 years of age; ~60%of this population has an early onset i.e. at the age of 0-2 years.
- The United States accounted for the highest number of Atopic dermatitis prevalent cases in the 7MM.
- Atopic Dermatitis Diagnosis remains of key importance. ~25% remain either undiagnosed or misdiagnosed. Also, a significant delay in diagnosis had been associated with the disease
- Of the Atopic Dermatitis Diagnosed Patients, more than 25% patients suffer with moderate to severe disease
- Among the available targeted therapies and biologics DUPIXENT (first approved therapy for AD) garners approximately USD 2 billion revenue by targeting moderate-to-severe patient category.
- Another promising class includes the JAK inhibitors with multiple approvals (OPZELURA, RINVOQ, CIBINQO, CORECTIM, and OLUMIANT) for atopic dermatitis.
- Although the Atopic Dermatitis Treatment armamentarium includes a plethora of drugs, ~40% patients still are managed on over the counter drugs, owing to dissatisfaction with efficacy and safety shown by the available prescription drugs.
- PDE4 inhibitors are and remain the only foreseeable treatment option for patients suffering from mild atopic dermatitis.
- As the US Food and Drug Administration(FDA) sets the Prescription Drug User Fee Act (PDUFA) date for July 2024, roflumilast can be the blockbuster drug by the end of the decade.
- In April 2024, Dermavent Sciences announced that the US Food and Drug Administration(FDA) has accepted Supplemental New Drug Application (sNDA) for VTAMA for the topical treatment of atopic dermatitis.
- Chugai’s MITCHGA (nemolizumab) approved in Japan for treating pruritus, the most cumbersome symptom associated with atopic dermatitis. The drug is anticipated to launch in the US by 2027.
Request for Unlocking the Sample Page of the "Atopic Dermatitis Treatment Market"
.jpg)
Factors Impacting the Atopic Dermatitis Market Growth
-
Rising Prevalence of Atopic Dermatitis
One of the major drivers of the atopic dermatitis market is the increasing prevalence of the condition across the globe. Atopic dermatitis affects both children and adults, with growing incidence rates being observed due to genetic predispositions, changing lifestyles, and environmental triggers. This rising patient pool creates sustained demand for advanced treatment options, fueling market growth.
-
Increasing Awareness and Diagnosis
Growing awareness about skin health, coupled with improved diagnostic capabilities, has significantly contributed to the expansion of the atopic dermatitis market. Public health campaigns, educational programs, and awareness initiatives by patient advocacy groups have helped in early identification and timely management of the disease, driving demand for therapeutic solutions.
-
Advancements in Biologic Therapies
The introduction and approval of biologics have revolutionized the atopic dermatitis treatment landscape. Targeted biologic therapies that offer long-term relief with fewer side effects compared to conventional treatments are increasingly being adopted. Continuous research and clinical trials exploring novel biologics and monoclonal antibodies further strengthen the market outlook.
Atopic Dermatitis Treatment Market Share Report Summary
- The Atopic Dermatitis Therapeutics Market Share Report offers extensive knowledge regarding the epidemiology segments (by region, prevalent cases of atopic dermatitis,age-specific prevalent cases, diagnosed prevalent cases, severity-specific diagnosed cases, gender-specific diagnosed cases, and total treated cases ) and predictions, presenting a deep understanding of the potential future growth in diagnosis rates, disease progression, and treatment guidelines. It provides comprehensive insights into these aspects, enabling a thorough assessment of the subject matter.
- Additionally, an all-inclusive account of the current management techniques and emerging therapies such as rocatinlimab, etrasimod and the elaborative profiles of late and mid-stage (Phase III and Phase II) and prominent therapies that would impact the current Atopic Dermatitis treatment market size and result in an overall market shift has been provided in the report.
- The Atopic Dermatitis Drugs Market report also encompasses a comprehensive analysis of the atopic dermatitis market, providing an in-depth examination of its historical and projected market size (2020–2034). It also includes the market share of therapies, detailed assumptions, and the underlying rationale for our methodology. The Atopic Dermatitis Drugs Market report also includes drug outreach coverage in the 7MM region.
- The Atopic Dermatitis Treatment Market Size report includes qualitative insights that provide an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, including experts from various hospitals and prominent universities, patient journey, and treatment preferences that help shape and drive the 7MM Atopic Dermatitis Drugs Market.
|
Study Period |
2020 to 2034 |
|
Forecast Period |
2024-2034 |
|
Geographies Covered |
The US, EU4 (Germany, France, Italy, and Spain), and the UK, Japan |
|
Atopic Dermatitis Market |
|
|
Atopic Dermatitis Treatment Market Size | |
|
Atopic Dermatitis Companies |
Bausch Health Companies Inc., GlaxoSmithKline PLC, Nestle SA, Pfizer Inc., Regeneron Pharmaceuticals Inc., Evelo Biosciences, Abbvie Inc., Allergan PLC, Cara Therapeutics, Bristol-Myers Squibb Company, Sanofi S.A., LEO Pharma, and others. |
|
Atopic Dermatitis Epidemiology Segmentation |
|
Atopic Dermatitis Drugs Market Share
- In 2023, the total Atopic Dermatitis Treatment Market Size in 7MM was around USD 17 billion, which is expected to increase by 2034 during the study period (2020–2034) in the 7MM.
- Among the 7MM, the United States accounted for the highest Atopic Dermatitis Treatment Market Size in 2023, followed by Japan for atopic dermatitis.
- During the forecast period (2024–2034), Atopic Dermatitis Pipeline candidates such as difelikefalin, orismilast and are expected to drive the rise in Atopic Dermatitis Market Size.
- By 2034, DUPIXENT is expected to garner one of the largest Atopic Dermatitis Market Share in the 7MM.
Recent Developments in the Atopic Dermatitis Market Landscape
- In September 2025, Incyte (Nasdaq: INCY) announced that the U.S. Food and Drug Administration (FDA) approved Opzelura® (ruxolitinib) cream 1.5% for the short-term and intermittent chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised children aged two years and older who have not responded adequately to topical prescription therapies or for whom such treatments are unsuitable.
- In May 2025, Teva Pharmaceutical and Biolojic Design announced that Teva had begun IND-enabling studies for BD9, a dual-specific multibody targeting TSLP and IL-13. Teva holds exclusive rights to develop BD9 for TH2-driven inflammatory diseases like atopic dermatitis and asthma.
- In February 2025, Galderma announced that the UK Medicines and Healthcare products Regulatory Agency and Swissmedic approved nemolizumab for treating moderate-to-severe atopic dermatitis and prurigo nodularis.
- In February 2025, the FDA granted fast-track designation to rezpegaldesleukin for treating moderate-to-severe atopic dermatitis in patients 12 and older whose condition is inadequately controlled with topical therapies or when those therapies are not suitable.
- In December 2024, Astria Therapeutics, Inc. announced that the FDA has cleared its Investigational New Drug (IND) application for STAR-0310, a monoclonal antibody OX40 antagonist. The company is developing STAR-0310 as a potential treatment for atopic dermatitis (AD) and other indications.
- In November 2024, Organon announced that the FDA extended the review period for the supplemental New Drug Application (sNDA) of VTAMA® (tapinarof) cream, 1%, for treating atopic dermatitis in adults and children over two years old. The new target action date is now set for March 12, 2025, a three-month extension from the original date of December 12, 2024.
Atopic Dermatitis Drugs Analysis
Atopic Dermatitis Marketed Therapies
-
RINVOQ (upadacitinib): AbbVie
-
DUPIXENT (dupilumab): Sanofi/Regeneron Pharmaceuticals
DUPIXENT (dupilumab) is an interleukin-4 (IL-4) receptor alpha antagonist. It is a human monoclonal antibody of the immunoglobulin G4 subclass that inhibits IL-4 and interleukin-13 (IL-13) signaling by specifically binding to the IL-4 receptor alpha subunit, which the IL-4 and IL-13 receptor complexes share. Dupilumab inhibits IL-4 signaling via the type 1 receptor and both IL-4 and IL-13 signaling via the type 2 receptor.
- The drug was invented using Regeneron’s VelocImmune technology which utilizes a proprietary genetically engineered mouse platform endowed with a genetically-humanized immune system to produce optimized fully-human antibodies.
Atopic Dermatitis Emerging Therapies
-
Rocatinlimab (KHK4083/AMG-451): Amgen/Kyowa Kirin
Rocatinlimab (KHK4083/AMG 451) is an anti-OX40 human monoclonal antibody that inhibits and reduces the number of OX40-expressing pathogenic T cells responsible for driving systemic and local inflammatory responses. It has been reported that effector T cells expressing OX40 are present in the lesions of patients with atopic dermatitis and are critical in the disease pathophysiology. The initial antibody was discovered in collaboration between Kyowa Kirin US Research and La Jolla Institute for Immunology.
-
- Currently, it is in Phase III of clinical development.
- In June 2021, Amgen and Kyowa Kirin announced an agreement to jointly develop and commercialize KHK4083 Phase III-ready anti-OX40 fully human monoclonal antibody in development for treating atopic dermatitis, with potential in other autoimmune diseases. Under the terms of the agreement, Amgen led the development, manufacturing, and commercialization of KHK4083 for all markets globally except Japan, where Kyowa Kirin retained all rights.
-
VTAMA (tapinarof; JTE-061): Dermavant Sciences/Japan Tobacco Pharmaceutical/Torii Pharmaceutical
Tapinarof is a novel aryl hydrocarbon receptor agonist in development as a once-daily, steroid-free, and cosmetically elegant topical cream. Dermavant is developing it for the treatment of psoriasis and atopic dermatitis. Over 1,400 subjects have participated in 12 clinical trials for tapinarof. In the US, VTAMA cream is approved for the topical treatment of plaque psoriasis in adults.
-
- In January 2020, Dermavant Sciences entered into a collaboration and license agreement with Japan Tobacco (JT) for exclusive rights to develop, register, and market tapinarof in Japan to treat dermatological diseases and conditions, including psoriasis and atopic dermatitis.
- In April 2024, Dermavant Sciences announced that it has submitted a Supplemental New Drug Application (sNDA) to the US FDA for VTAMA (tapinarof) cream, 1% for the topical treatment of atopic dermatitis in adults and children 2 years of age and older.
.jpg)
Atopic Dermatitis Market Outlook
Several effective Atopic Dermatitis treatments have become available in recent years for adult and adolescent patients with Atopic Dermatitis, and more are in development. The current Atopic Dermatitis market uses several off-label therapies apart from pharmacological systemic treatment.
Localized atopic itch is frequently treated with topical or intralesional therapeutic agents. Topical corticosteroids have been used for atopic dermatitis for decades. Pimecrolimus and tacrolimus, topical calcineurin inhibitors, are used as steroid-sparing agents for patients with atopic dermatitis. Phosphodiesterase-4 (PDE-4) inhibitors are an alternative option for the topical treatment of pruritis in atopic dermatitis. Oral antihistamines are commonly used for atopic itch. Additionally, phototherapy is efficacious in targeting atopic itch.
Systemic pharmacologic treatments have proven to be beneficial in patients who are unresponsive to topical therapies. DUPIXENT (dupilumab) is an interleukin-4 receptor alpha antagonist indicated for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. It was the first pharmacological treatment approved in 2017.
- The current US market possesses DUPIXENT, OPZELURA, RINVOQ, EUCRISA, CIBINQO, and ADBRY/ADTRALZA to treat patients with atopic dermatitis.
- In EU4 and the UK, the current market holds DUPIXENT, RINVOQ, CIBINQO, and ADBRY/ADTRALZA for the treatment of atopic dermatitis.
- The treatment in Japan for atopic dermatitis is similar to that of the US and EU4, and the UK. The Japanese market uses DUPIXENT, RINVOQ, CIBINQO, ADBRY/ADTRALZA, CORECTIM, OLUMIANT, MOIZERTO, and MITCHGA.
Conclusively, while the treatment of atopic itch is challenging, advancements in the last several years have provided multiple options ranging from topical agents to systemic therapies. In addition, newer treatments on the horizon hold great promise. Moreover, improved treatment of atopic itch will improve atopic dermatitis symptoms and the quality of life in many patients across 7MM.
Atopic Dermatitis Disease Understanding
Atopic dermatitis, also called eczema, is a chronic condition and the most common type of skin inflammation that usually starts in early childhood but can occur at any age and can be recurrent or persistent throughout life. In ‘dermatitis,’ ‘derm’ means ‘skin,’ and ‘itis’ means ‘inflammation.’ Thus, dermatitis is a skin inflammation characterized by itchiness, redness, and a rash caused by genetics, an overactive immune system, infections, allergies, and irritating substances. Half of the patients with moderate-to-severe eczema also have asthma, hay fever (allergic rhinitis), and food allergies; it is the most common chronic skin disease in children.
- The primary symptom of atopic dermatitis is dry, itchy skin that often turns into a red rash; during a flare, it becomes a red, itchy rash. Many different physical and internal factors can trigger an eczema flare-up. The resulting inflammation causes increased blood flow and the urge to itch. Eczema flares are part of the agonizing itch-scratch cycle that is hard to fight, leading to more inflammation and even skin infections.
- Atopic Dermatitis presents different symptoms depending on the age of the person. Itching is the hallmark of atopic dermatitis; more than 85% of people experience this distressing symptom daily; sore or painful skin and poor sleep caused by itching are also common.
Further details are provided in the report…
Atopic Dermatitis Diagnosis
No specific test for atopic dermatitis exists, and no single symptom or feature can be used to identify the disease. Each patient has a unique combination of symptoms and rash appearance. Atopic dermatitis diagnosis is based on the history and physical examination of the patient. In uncertain cases, a skin biopsy may be taken for a histopathological diagnosis of dermatitis.
Features considered when making a diagnosis are summarized in the following table:
Further details related to country-based variations are provided in the report…
Atopic Dermatitis Treatment
Eczema is a condition wherein patches of skin become inflamed, itchy, cracked, and rough. Different types and stages of eczema affect a large segment of the population in the 7MM. The word eczema is often used to refer to atopic dermatitis, the most common type of persistent skin disease that usually starts in early childhood.
The significant psychological, social, and emotional impact is experienced by people with the condition daily. In addition to visual and physical issues, atopic dermatitis can significantly impact people’s quality of life (QoL). There is no cure for AD; however, it can be effectively managed with current treatment options. The pattern of the disease and its severity determine the kind of treatment the patient ought to receive.
- The current US, European and Japanese markets for atopic dermatitis are dominated by topical treatment options such as emollients, topical corticosteroids (TCS) + antibiotics, topical calcineurin inhibitors (TCIs), and systemic treatment such as immunosuppressants, corticosteroids, DUPIXENT (dupilumab), and others (phototherapy).
.jpg)
Atopic Dermatitis Epidemiology
The Atopic Dermatitis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by prevalent cases of atopic dermatitis, age-specific prevalent cases, diagnosed prevalent cases, severity-specific diagnosed cases, gender-specific diagnosed cases, and total treated cases in the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2020 to 2034.
Atopic Dermatitis Epidemiological Analysis
- In 7MM, the US accounted for ~33,000 Atopic Dermatitis Prevalent Cases.
- It has been observed that the Atopic Dermatitis Prevalence is higher in children as compared to adults in the 7MM.
- Among the EU4 and the UK, the United Kingdom accounted for the highest number of Atopic Dermatitis diagnosed prevalent cases, followed by France, whereas Spain accounted for the lowest number of atopic dermatitis cases.
- In 2023, as far as severity-specific cases are concerned, mild cases accounted for the highest number of cases in Japan. These cases are anticipated to increase by 2034.
Atopic Dermatitis Epidemiological Segmentation
- Atopic Dermatitis Prevalent Cases
- Atopic Dermatitis Age-specific Prevalent Cases
- Atopic Dermatitis Diagnosed Prevalent Cases
- Atopic Dermatitis Severity-specific Diagnosed Cases
- Atopic Dermatitis Gender-specific diagnosed cases
- Total Atopic Dermatitis Treated Cases
Latest KOL Views on Atopic Dermatitis
To stay abreast of the latest trends in the Atopic Dermatitis Drugs Market, we conduct primary research by seeking the opinions of Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) who work in the relevant field. This helps us fill any gaps in data and validate our secondary research. We have reached out to industry experts to gather insights on various aspects of atopic dermatitis, including the evolving Atopic Dermatitis treatment market size landscape, patients’ reliance on conventional therapies, their acceptance of therapy switching, drug uptake, and challenges related to accessibility. The experts we contacted included medical/scientific writers, professors, and researchers from prestigious universities in the US, Europe, the UK, and Japan.
Our team of analysts at DelveInsight connected with more than 10 KOLs across the 7MM. By obtaining the opinions of these experts, we gained a better understanding of the current and emerging treatment patterns in the atopic dermatitis market, which will assist our clients in analyzing the overall epidemiology and market scenario.
Atopic Dermatitis Therapeutics Market: Qualitative Analysis
We perform Qualitative and Atopic Dermatitis Therapeutics Market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst’s discretion and assessment of the patient burden, cost analysis, and existing and evolving Atopic Dermatitis treatment market size.
Conjoint analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, designation, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy. In efficacy, the trial’s primary and secondary outcome measures are evaluated. Based on these, the overall efficacy is evaluated.
Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
Atopic Dermatitis Therapeutics Market Access and Reimbursement
Because newly authorized Atopic Dermatitis drugs are often expensive, some patients escape receiving proper treatment or use off-label, less expensive prescriptions. Reimbursement plays a critical role in how innovative treatments can enter the market. The cost of the medicine, compared to the benefit it provides to patients who are being treated, sometimes determines whether or not it will be reimbursed.
Regulatory status, target population size, the setting of treatment, Atopic Dermatitis unmet needs, the number of incremental benefit claims, and prices can all affect market access and reimbursement possibilities. The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.
Atopic Dermatitis Treatment Market Size Report Insights
- Patient-based Atopic Dermatitis Market Forecasting
- Therapeutic Approaches
- Atopic Dermatitis Treatment Market Size
- Atopic Dermatitis Market Trends
- Existing Atopic Dermatitis Drugs Market Opportunity
Atopic Dermatitis Therapeutics Market Report Key Strengths
- 11 Years- Atopic Dermatitis Market Forecast
- The 7MM Coverage
- Atopic Dermatitis Epidemiology Segmentation
- Key Cross Competition
Atopic Dermatitis Treatment Market Size Report Assessment
- Current Atopic Dermatitis Treatment Market Practices
- Reimbursements
- Atopic Dermatitis Drugs Market Attractiveness
- Qualitative Analysis (SWOT, Conjoint Analysis, Unmet Needs)
Key Questions Answered in the Atopic Dermatitis Market Report
Atopic Dermatitis Market Insights
- Would there be any changes observed in the current Atopic Dermatitis treatment approach?
- Will there be any improvements in Atopic Dermatitis management recommendations?
- Would research and development advances pave the way for future tests and Atopic Dermatitis therapies?
- Would the diagnostic testing space experience a significant impact and lead to a positive shift in the Atopic Dermatitis treatment market size landscape?
- What kind of uptake will the new therapies witness in the coming years in Atopic Dermatitis patients?
Stay Updated:-
